Critical Reviews in Oncology / Hematology
Volume 76, Issue 1 , Pages 36-43 , October 2010

The potential role of sunitinib in gastrointestinal cancers other than GIST

  • Cristina Grávalos

      Affiliations

    • Medical Oncology Department, 12 de Octubre Universitary Hospital, Avda. de Andalucía s/n Km 5.400, 28041 Madrid, Spain
    • Corresponding Author InformationCorresponding author. Tel.: +34 91 390 83 49; fax: +34 91 460 33 10.
    • ,
  • Enrique Grande

      Affiliations

    • Medical Oncology Department, Ramon y Cajal Universitary Hospital, Madrid, Spain
    • ,
  • Joan Manel Gasent

      Affiliations

    • Medical Oncology Department, Hospital Marina Alta de Denia, Alicante, Spain

,Accepted 6 January 2010.

References 

  1. Elkord E, Hawkins RE, Stern PL. Immunotherapy for gastrointestinal cancer: current status and strategies for improving efficacy. Expert Opin Biol Ther. 2008;8(4):385–395
  2. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100:57–70
  3. Dvorak HF. Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol. 2002;20:4368–4380
  4. Morabito A, De Maio E, Di Maio M, et al. Tyrosine kinase inhibitors of vascular endothelial growth factor receptors in clinical trials: current status and future directions. Oncologist. 2006;11:753–764
  5. McCarty MF, Somcio RJ, Stoeltzing O, et al. Overexpression of PDGF-BB decreases colorectal and pancreatic cancer growth by increasing tumor pericyte content. J Clin Invest. 2007;117:2114–2122
  6. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal cell carcinoma. N Engl J Med. 2007;356:115–124
  7. Demetri GD, van Oosterom AT, Garret CR, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumor after failure of imatinib: a randomised controlled trial. Lancet. 2006;368:1329–1338
  8. Chow LQM, Eckhardt SG. Sunitinib: from rational design to clinical efficacy. J Clin Oncol. 2007;25(7):884–896
  9. Faivre S, Delbaldo C, Vera K, et al. Safety, Pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol. 2006;24:25–35
  10. Izzedine H, Billemont B, Thibault F, Rixe O. New challenges in kidney cancer therapy: sunitinib. Ann Oncol. 2007;18(Suppl 9):ix83–ix86
  11. Bello CL, Sherman L, Zhou J, et al. Effect of food on the pharmacokinetics of sunitinib malate (SU11248), a multitargeted receptor tyrosine kinase inhibitor: results from a phase I study in healthy subjects. Anti-Cancer Drugs. 2006;17:353–358
  12. Rini BI. Sunitinib. Expert Opin Pharmacother. 2007;8:2359–2369
  13. Houk E, Bello C, Michaelson D, et al. Exposure-response of sunitinib in metastatic renal cell carcinoma (mRCC): a population pharmacokinetic/pharmacodynamic (PKPD) approach. ASCO Annual Meeting Proceedings Part I. J Clin Oncol. 2007;[vol. 25, No. 18S (June 20 Supplement); 2007: 5027]
  14. Galizia G, Lieto E, Ferraraccio F, et al. Determination of molecular marker expression can predict clinical outcome in colon carcinomas. Clin Cancer Res. 2004;10:3490–3499
  15. Takahashi Y, Kitadai Y, Bucana CD, et al. Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer. Cancer Res. 1995;55:3964–3968
  16. Kopetz S, Chang GJ, Overman MJ, et al. Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J Clin Oncol. 2009;27(22):3677–3683
  17. Saltz LB, Rosen LS, Marshall JL, et al. Phase II trial of sunitinib in patients with metastatic colorectal cancer after failure of standard therapy. J Clin Oncol. 2007;25:4793–4799
  18. Mendel DB, Laird AD, Xin X, et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res. 2003;9:327–337
  19. Marzola P, Degrassi A, Calderan L, et al. Early antiangiogenic activity of SU11248 evaluated in vivo by dynamic contrast-enhanced magnetic resonance imaging in an experimental model of colon carcinoma. Clin Cancer Res. 2005;11(16):5827–5832
  20. Leong S, Eckhardt SG, Chan E, et al. A phase I study of sunitinib in combination with modified FOLFOX6 chemotherapy. Gastrointestinal Cancers Symposium. 2007;(abstract 285)
  21. Starling N, Vazquez F, Cunningham D, et al. Phase I study to evaluate the safety and efficacy of sunitinib in combination with FOLFIRI in treatment-naïve metastatic colorectal cancer. J Clin Oncol. 2008;26;(abstract 3563)
  22. Pfizer Discontinues Phase 3 Trial of Sutent® in Metastatic Colorectal Cancer. Available at: http://www.pfizer.com/news/press_releases/pfizer_press_releases.jsp [Accessed July 20, 2009].
  23. Aklilu M, Ilson DH. Targeted agents and esophageal cancer—the next step. Semin Radiat Oncol. 2006;17:62–69
  24. Christensen JG. A preclinical review of sunitinib, a multitargeted receptor tyrosine kinase inhibitor with anti-angiogenic and antitumor activities. Ann Oncol. 2007;18(Suppl 10):x3–x10
  25. Bang Y, Kang Y, Kang W, et al. Sunitinib as second line treatment for advanced gastric cancer: preliminary results from a phase II study. J Clin Oncol. 2007;25(18S):(abstract 4603)
  26. Zhu AX. Development of sorafenib and other molecularly targeted agents in hepatocellular carcinoma. Cancer. 2008;112:250–259
  27. Llovet J, Ricci S, Mazzaferro V, et al. Sorafenib improves survival in advanced hepatocellular carcinoma (HCC): results of a phase III randomized placebo-controlled trial (SHARP trial). N Engl J Med. 2008;359:378–390
  28. Faivre S, Raymond E, Boucher E, et al. Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study. Lancet Oncol. 2009;10(August (8)):794–800[Epub 2009 July 6]
  29. Zhu AX, Sahani DV, Duda DG, et al. Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study. J Clin Oncol. 2009;27(18):3027–3035
  30. De Primo SE, Cheng AL, Lanzalone S, et al. Circulating biomarkers of sunitinib in patients with unresectable hepatocellular carcinoma (HCC): analysis of correlations with outcome and tumor imaging parameters. J Clin Oncol. 2008;26:(abstract 4593)
  31. Seo Y, Baba H, Fukuda T, et al. High expression of vascular endothelial growth factor is associated with liver metastasis and a poor prognosis for patients with ductal pancreatic adenocarcinoma. Cancer. 2000;88:2239–2245
  32. Cuneo KC, Geng L, Fu A, et al. SU11248 (sunitinib) sensitizes pancreatic cancer to the cytotoxic effects of ionizing radiation. Int J Radiation Oncol Biol Phys. 2008;71:873–879
  33. O’Reilly EM, Niedzwiecki D, Hollis D, et al. A phase II trial of sunitinib in previously treated pancreas adenocarcinoma, CALGB 80603. J Clin Oncol. 2008;26:(abstract 4515)
  34. Strosberg JR, Kvols LK. A review of the current clinical trials for gastroenteropancreatic neuroendocrine tumors. Expert Opin Investig Drugs. 2007;16:219–224
  35. Hager JH, Hanahan D. Tumor cells utilize multiple pathways to down-modulate apoptosis. Lessons from a mouse model of islet cell carcinogenesis. Ann N Y Acad Sci. 1999;887:150–163
  36. Pietras K, Hanahan D. A multitargeted, metronomic, and maximum-tolerated dose “chemo-switch” regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer. J Clin Oncol. 2005;23:939–952
  37. Kulke MH, Lenz HJ, Meropol NJ, et al. Activity of sunitinib in patients with advanced neuroendocrine tumors. J Clin Oncol. 2008;26:3403–3410
  38. Raymond E, Raoul JL, Niccoli P, et al. Phase III, randomized, double-blind trial of Sunitinib vs placebo in patients with progressive, well-differentiated, malignant pancreatic islet cell tumors. In: Presented as oral communication at the World Gastrointestinal Congress. 2009;(abstract O-0013)
  39. Yoshikawa D, Ojima H, Iwasaki M, et al. Clinicopathological and prognostic significance of EGFR, VEGF, and HER2 expression in cholangiocarcinoma. Br J Cancer. 2008;29:418–425
  40. Clark JW, Meyerhardt JA, Sahani DV, et al. Phase II study of gemcitabine, oxaliplatin in combination with bevacizumab (GEMOX-B) in patients with unresectable or metastatic billiary tract and gallbladder cancers. J Clin Oncol. 2007;25(18S):(abstract 4625)
  41. Huether A, Höpfner M, Baradari V, et al. Sorafenib alone or as combination therapy for growth control of cholangiocarcinoma. Biochem Pharmacol. 2007;73:1308–1317

PII: S1040-8428(10)00009-0

doi: 10.1016/j.critrevonc.2010.01.008

Critical Reviews in Oncology / Hematology
Volume 76, Issue 1 , Pages 36-43 , October 2010

Article Tools

* Image Usage & Resolution